Oral chemotherapy in colorectal cancer treatment: review of the literature |
| |
Authors: | Kurtz Jean Emmanuel Andrès Emmanuel Natarajan-Amé Shanti Noel Esther Dufour Patrick |
| |
Institution: | 1. Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite University, PO Box 150459, Zarqa 13115, Jordan;2. School of Veterinary and Life Sciences, Murdoch University, Murdoch, WA 6150, Australia;1. Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States;4. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States;5. Apogee Biotechnology Corporation, Hummelstown, PA, United States |
| |
Abstract: | Recent advances in anticancer treatment have focused on the development of oral anticancer agents with the intention of improving the patients' quality of life as well as providing therapeutic alternatives to intravenous chemotherapy. Until agents such as oxaliplatin and irinotecan became available, the treatment of colorectal cancer, one the most common cancers diagnosed in industralized countries, was mainly based on 5-fluorouracil modulation. The overwhelming majority of these new drugs are pyrimidine analogues intended to replace intravenous treatment or to make the therapy more acceptable to the patients. In this article, the use of oral chemotherapy, alone or in combination with radiotherapy, in colorectal cancer is reviewed and updated. The rationale for using oral compounds is discussed and newer agents, such as oral camptothecin analogues and antiangiogenic agents, are presented with the results of their clinical and preclinical developments. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|